Sarepta Therapeutics (NASDAQ:SRPT) Sets New 1-Year Low on Analyst Downgrade

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) hit a new 52-week low during mid-day trading on Thursday after Royal Bank of Canada lowered their price target on the stock from $165.00 to $161.00. Royal Bank of Canada currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $101.00 and last traded at $108.35, with a volume of 150140 shares trading hands. The stock had previously closed at $106.86.

A number of other brokerages also recently issued reports on SRPT. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday. Evercore ISI dropped their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Finally, Guggenheim lifted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $173.52.

Insider Buying and Selling

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Sarepta Therapeutics by 11.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company’s stock valued at $36,392,000 after purchasing an additional 31,098 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $5,713,000. Vestal Point Capital LP bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $30,398,000. Finally, Vident Advisory LLC bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $357,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market cap of $10.20 billion, a P/E ratio of 85.40 and a beta of 0.75. The firm’s fifty day moving average price is $115.89 and its 200 day moving average price is $122.61.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.